Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Announces A Corporate Restructuring Plan To Maximize On The Value Of FT218 – FDA Headlines
lost 10.67% in the previous trading session here is the reason why the stock is
hitting new lows. The pharmaceutical company has also set records right
regarding its corporate restructuring activities, which have been under massive
speculation. According to the companys interim Chief Executive Officer, Greg
Divis, the restructuring will add more value to the FT218.
The once-nightly formulation of sodium oxybate is in the Phase III stage of its development. Divis says that this far it is the most promising asset to the company. If approved, we believe FT218, with once-nightly dosing, will provide a significant improvement for patients over the current standard-of-care, he states.